
130.6K
Downloads
269
Episodes
Molecule to Market takes you inside the global pharma and biopharma outsourcing ecosystem. Each week, our host Raman Sehgal sits down with the founders, entrepreneurs, CEOs and C-suite leaders shaping the pharma services and tools that power discovery, drug development and commercialization.
Listeners get real stories and practical insights from across the entire value chain, from big pharma and emerging biotechs to private equity investors, CROs, CDMOs, technology platforms and specialist consulting firms. Our host Raman is an entrepreneur, investor, bestselling author, speaker and long time industry insider.
https://moleculetomarketpod.com
Molecule to Market takes you inside the global pharma and biopharma outsourcing ecosystem. Each week, our host Raman Sehgal sits down with the founders, entrepreneurs, CEOs and C-suite leaders shaping the pharma services and tools that power discovery, drug development and commercialization.
Listeners get real stories and practical insights from across the entire value chain, from big pharma and emerging biotechs to private equity investors, CROs, CDMOs, technology platforms and specialist consulting firms. Our host Raman is an entrepreneur, investor, bestselling author, speaker and long time industry insider.
Episodes

Friday May 23, 2025
The pharma CEO focused on US commercial growth
Friday May 23, 2025
Friday May 23, 2025
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Adriana Herrera, CEO at Pierre Fabre Pharmaceuticals (USA).
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adriana, covering:
- Why Big Pharma is such a great training ground for future pharma leaders, and how a period living and working in Mexico defined her leadership style
- The reality of being purchased by a big pharma like Gilead, and retaining independence as the acquired company, Kite Pharma
- The opening of a market opportunity that led Adriana to her first CEO role, and how the role is pushing her outside of her comfort zone
- Why she is optimistic about the future of manufacturing and commercialising cell therapies - innovation will find a way, but it takes time
- How the current geopolitical environment is adding more risk and uncertainty to an industry plagued with risk... and how that may impact investments and supply chains
Adriana leads the expansion of Pierre Fabre’s US presence in precision oncology, cell therapy and rare diseases with an immediate focus on the commercialization of a groundbreaking allogenic cell therapy.
Most recently, Adriana served as U.S. General Manager at Kite Pharma where she successfully commercialized the autologous CART-cell therapy portfolio and led the US commercial functions. Prior to that, her experience included a tenure at Eisai as Senior Vice President and commercial head for U.S. Oncology and high-impact leadership roles at Novartis Oncology including Vice President and Global Diseases Lead for Lung and Genitourinary cancers. Adriana commenced her career at Bristol Myers-Squibb.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

No comments yet. Be the first to say something!